Open
透過自主開發(fā)的新穎性微管陣列薄膜，並結(jié)合美國(guó)國(guó)家癌癥研究所開發(fā)的中空纖維測(cè)定法， 可針對(duì)藥廠提供短時(shí)間內(nèi)抗癌藥物之開發(fā)及協(xié)助提高臨床二期實(shí)驗(yàn)通過率；此外提供癌癥病患個(gè)人化精準(zhǔn)用藥篩選服務(wù)及提供醫(yī)師選擇抗癌藥物治療時(shí)之科學(xué)數(shù)據(jù)參考。
The MTAM-HFA is based on the US National Cancer Institute (NCI) developed technique known as the Hollow Fiber Assay (HFA). We introduce a new component known as the Microtube Array Membrane (MTAM) which consists of a whole host of beneficial microstructures which are patented. The combination of tumor cells (primary/cell line) which can be solid or non-solid, which are then siphoned into the lumens of the MTAMs; fused and subcutaneously implanted into the backs of Balb/C mice. Anti-cancer drugs (small molecule, protein, immunotherapy, cell therapy*) are administered accordingly and the entire test can be completed within 14 days.
The MTAM-HFA is based on the US National Cancer Institute (NCI) developed technique known as the Hollow Fiber Assay (HFA). We introduce a new component known as the Microtube Array Membrane (MTAM) which consists of a whole host of beneficial microstructures which are patented. The combination of tumor cells (primary/cell line) which can be solid or non-solid, which are then siphoned into the lumens of the MTAMs; fused and subcutaneously implanted into the backs of Balb/C mice. Anti-cancer drugs (small molecule, protein, immunotherapy, cell therapy*) are administered accordingly and the entire test can be completed within 14 days.